ALBO - Mirum Is Undervalued Despite Expected Tough Competition

• Mirum aims to be a leader in the treatment of rare liver diseases for which the unmet medical need is high.
• Mirum is developing Maralixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications with a market potential in the billions.
• Maralixibat is expected to be approved for ALGS in the U.S. and for PFIC2 in Europe later this year, with a PDUFA date of September 29, 2021.
• In addition to Maralixibat, Volixibat is being evaluated for efficacy in three indications in registrational studies.
• The potential sale of a PRV will further strengthen Mirum's financial position ahead of commercialization.

For further details see: